Licensing
DxS Ltd has granted DuPont Qualicon a license to apply its Scorpions technology for the development of diagnostics that test for pathogens in the food industry.
Scorpions is a rapid and reliable fluorescence-based signal generation system that can be used to test for the presence of any gene. DxS, a spin out of AstraZeneca’s diagnostics division in the UK, is applying the technology to the development of theranostic tests that identify which patients will respond to a particular cancer drug.
Kevin Huttman, President of DuPont Qualicon, said, “With Scorpions’ cutting-edge technology, we can develop increasingly faster, more sensitive tests for pathogens and spoilage organisms that anticipate and satisfy the evolving needs of the food industry for safer, higher quality products.”
Stephen Little, CEO of DxS, said, “Scorpions has unparalleled sensitivity and specificity making it ideal for detecting often difficult to find organisms which may not be identifiable through other diagnostic platforms.” Financial terms were not disclosed.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
